News
A dry powder inhaler formulation provides excellent protection against pneumonia-causing bacteria, scientists report. Community-acquired pneumonia, a type of lung inflammation contracted outside ...
A case study will also be presented, in which an inhaled formulation of the antibody bevacizumab demonstrated 24-month stability at 25°C. Key Learning Objectives. Understand formulation approaches for ...
Successful drug delivery via a dry powder inhaler is determined by the API physicochemical properties, the formulation composition and process, the device and operating conditions, the patient–device ...
Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the ...
LONDON, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical compa ...
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 ...
ProAir RespiClick will be available as a dry-powder inhaler containing 200 actuations and 0.65g of the formulation. Each dose delivers 108mcg of albuterol sulfate (equivalent to 90mcg of albuterol ...
DALLAS — A dry powder formulation of treprostinil was safe and well tolerated at 2 months, with no drug-related serious adverse events, in patients with pulmonary arterial hypertension ...
CRYSTAL LAKE, Ill., November 07, 2024--Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results